NewAmsterdam Pharma Co N.V. (NAMS) has 5 SEC Form 4 insider filings on record in the last 90 days. That includes 1 insider purchase totalling $226K, and 1 sales totalling $41K. Most recent filing: Sept. 15, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 15, 2026 filed Sept. 14, 2026 | Davidson Michael H. Chief Executive Officer | +$226,500 | 10,000 | +1% | No | |
|
|
||||||
| Sept. 9, 2026 filed Sept. 4, 2026 | Smither John W Director | −$40,512 | 1,600 | −15% | No | |
|
|
||||||
| Aug. 25, 2026 filed Aug. 24, 2026 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | $3,363,750 | 375,000 | 0% | Yes | |
|
|
||||||
| July 22, 2026 filed July 20, 2026 | Kooij Louise Frederika Chief Accounting Officer | $1,936,156 | 315,000 | 0% | Yes | |
|
|
||||||
| June 24, 2026 filed June 22, 2026 | Kooij Louise Frederika Chief Accounting Officer | $772,159 | 120,000 | 0% | Yes | |
|
|
||||||
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free